Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DB-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Direct Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the terms of the agreement, Direct Biologics will leverage Bioclinica’s Interactive Response Technology (IRT) for their EXIT COVID-19 study, a multi-center FDA phase II clinical trial for the use of ExoFlo™ to treat COVID-19 acute respiratory d...
Brand Name : ExoFlo
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 09, 2020
Lead Product(s) : DB-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Direct Biologics
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?